A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
Sponsor: Hutchmed
Terminated
The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns
Other terminated trials from Hutchmed
Other Isocitrate Dehydrogenase Gene Mutation trials with similar outcome
This PHASE1 trial investigates Isocitrate Dehydrogenase Gene Mutation and is currently terminated or withdrawn. Hutchmed leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Nov 2024 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2023 — Mar 2024 [monthly]
Recruiting PHASE1
-
Feb 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Mar 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hutchmed
For direct contact, visit the study record on ClinicalTrials.gov .